Liver Enzyme Elevations Reported in Tigecycline Trials
Tigecycline, an IV glycylcycline antibiotic, shows liver enzyme increases (primarily ALT and AST) as a common adverse event. In phase 3 and 4 clinical trials across indications like complicated skin/skin structure infections (cSSSI), intra-abdominal infections (cIAI), and ventilator-associated pneumonia, elevations >3x upper limit of normal (ULN) occurred in 1-9% of tigecycline patients versus 0-4% in comparators (e.g., vancomycin+piperacillin/tazobactam or imipenem). Overall incidence of any elevation is higher, around 15-30% for mild increases (>1x ULN).[1][2]
How Frequency Breaks Down by Severity and Trial
- Mild to moderate (>1x to ≤3x ULN): Seen in 20-25% of patients in pooled safety data from 13 trials (n=3,791 tigecycline patients).
- Severe (>6x ULN or >10x ULN): 0.5-2%, with rare cases (>20x ULN) in <0.5%. Most resolve post-treatment without intervention.
Frequency varies by dose (50 mg BID standard) and population—higher in hepatic impairment or prolonged use (>14 days).[1][3]
Factors Driving Higher Rates in Real-World Use
Post-marketing data and meta-analyses report 10-15% incidence of transaminase rises, often linked to concomitant hepatotoxins (e.g., other antibiotics) or comorbidities like fatty liver. No direct causality established, but tigecycline inhibits bile acid transporters, potentially contributing.[2][4] In hospital settings, monitoring every 7-14 days is standard.
Comparison to Other Antibiotics
Tigecycline's rate exceeds beta-lactams (e.g., 5-10% for piperacillin/tazobactam) but matches or is below tetracyclines like doxycycline (15-20%). It's lower than linezolid (up to 10% severe) in pneumonia trials.[1][5]
When Do Elevations Peak and Resolve?
Typically within 7-10 days of starting therapy, peaking early in treatment. 90% resolve within 7 days of discontinuation; <1% lead to hepatic failure.[2][3]
Sources
[1]: Tygacil (tigecycline) Prescribing Information, Pfizer
[2]: FDA Adverse Event Reporting System (FAERS) Summary
[3]: Meagher et al., Clin Infect Dis 2005; Pooled Analysis
[4]: DrugPatentWatch.com - Tigecycline Safety Profile
[5]: Tasina et al., Eur J Clin Microbiol Infect Dis 2011; Meta-analysis